EPM2A: A Potential Drug Target and Biomarker (G7957)

Target Name: EPM2A

NCBI ID: G7957

EPM2A

EPM2A: A Potential Drug Target and Biomarker

EPM2A, short for Enhanced Programmed Medication Therapy, is a drug target and biomarker that has been identified as a potential target for future drug development. It is a transmembrane protein that is expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract. Its function is not well understood, but it is thought to play a role in the regulation of insulin secretion and glucose uptake and storage.

One of the key challenges in the development of new drugs is identifying potential targets and biomarkers. EPM2A is an attractive target because it is involved in a fundamental biological process that is relevant to many diseases, including diabetes and obesity. It is also a potential biomarker because it can be easily measured and targeted using small molecules or antibodies.

EPM2A is a transmembrane protein that is expressed in the brain, pancreas, and gastrointestinal tract. It is made up of four structural domains: an N-terminus, a transmembrane domain, a C-terminus, and an optional Z-terminal region. The N-terminus is responsible for the protein's cytoplasmic localization, while the C-terminus is responsible for its plugin to the endosomal system, which is a mechanism for the transport of proteins to the plasma membrane.

The function of EPM2A is not well understood, but it is thought to play a role in the regulation of insulin secretion and glucose uptake and storage. Insulin is a hormone that is produced by the pancreas and helps to regulate blood sugar levels. EPM2A has been shown to interact with the protein TrkB, which is a key regulator of insulin secretion. This suggests that EPM2A may be involved in the regulation of insulin secretion by TrkB.

EPM2A has also been shown to be involved in the regulation of glucose uptake and storage. Glucose is the body's primary energy source, and it is important for maintaining brain function and fueling the body's activities. EPM2A has been shown to interact with the protein SREBP, which is a transcription factor that regulates the expression of genes involved in glucose uptake and storage. This suggests that EPM2A may be involved in the regulation of glucose uptake and storage by SREBP.

EPM2A is a potential drug target because it is involved in a fundamental biological process that is relevant to many diseases, including diabetes and obesity. It is also a potential biomarker because it can be easily measured and targeted using small molecules or antibodies. Further research is needed to fully understand the function of EPM2A and its potential as a drug target and biomarker.

Protein Name: EPM2A Glucan Phosphatase, Laforin

The "EPM2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPM2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets